PMID- 33361021
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 33
IP  - 3(Special)
DP  - 2020 May
TI  - Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke 
      patients with Alzheimer disease: A potential therapeutic option.
PG  - 1349-1354
AB  - This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor 
      in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer 
      disease (AD). In the present clinical trial, Chinese elderly patients aged >/=65 
      years with a confirmed diagnosis of AD were enrolled. The patients received MAO-B 
      inhibitor (Selegiline 5 mg) or DNP 10 mg daily (reference) for 6 months. The 
      efficacy and safety data were collected from 120 patients (60 patients in each 
      group) every 3 weeks until 6 months. The primary endpoints were to assess the 
      change in cognitive score from baseline in both the treatment group. The result 
      of the present study showed that the patients treated with MAO-B inhibitor and 
      DNP have similar efficacy and safety profile Considering the clinical benefit, 
      mean (SD) improvement in sign and symptoms was numerically greater in DNP-treated 
      patients as compared to MAO-B inhibitor at endpoint visit (SIB: 12.3 (3.7) vs 
      11.3 (4.2); AD severity: 14.2 (3.5); CIBIS+/CIBIC: 10.2 (2.7) vs 9.4 (3.2); 
      ADCS-ADL: 14.3 (4.2) vs 13.2 (3.4); MMSE: 14.3 (3.7) vs 12.2 (3.2), P>0.05 
      respectively for each comparison). However, a statistical difference in terms of 
      clinical benefit was similar between both the treatment groups (p>0.05). Overall, 
      both the study drugs were found comparable in relieving the symptoms of AD 
      (severity score after end of treatment: 14.2 vs 13.4 respectively; p >0.05). This 
      indicates that MAO-B inhibitor is a potential target for the treatment of AD in 
      China. The results of the present study may help to design a large clinical trial 
      to evaluate the efficacy and safety of MAO-B inhibitor in comparison with DNP in 
      AD patients.
FAU - Yang, Huaqing
AU  - Yang H
AD  - Department of Neurology, Central Hospital of Xinwen Mining Group Co., Ltd., 
      Xintai, Shandong, China.
FAU - Han, Weidong
AU  - Han W
AD  - Department of Neurology, Central Hospital of Xinwen Mining Group Co., Ltd., 
      Xintai, Shandong, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Anesthesiology, Suzhou Ninth People's Hospital, Jiangsu, China.
LA  - eng
PT  - Clinical Study
PT  - Comparative Study
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Nootropic Agents)
RN  - 2K1V7GP655 (Selegiline)
RN  - 8SSC91326P (Donepezil)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Alzheimer Disease/complications/diagnosis/*drug therapy/psychology
MH  - China
MH  - Cholinesterase Inhibitors/adverse effects/*therapeutic use
MH  - Cognition/*drug effects
MH  - Donepezil/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Monoamine Oxidase Inhibitors/adverse effects/*therapeutic use
MH  - Nootropic Agents/adverse effects/*therapeutic use
MH  - Pilot Projects
MH  - Random Allocation
MH  - Selegiline/adverse effects/*therapeutic use
MH  - Stroke/*complications/diagnosis/psychology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2020/12/29 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2020 May;33(3(Special)):1349-1354.